| Page 12 | Aplastic Anemia and MDS International Foundation

Promising new advances in AML therapy

Drug therapy for acute myeloid leukemia (AML) is finally undergoing major changes in 2017. This is due to the US Food and Drug Administration’s approval of several new, targeted agents (midostaurin, enasidenib, and gemtuzumab ozogamicin). Paired with the recent approval of a novel liposomal formulation of daunorubicin/cytarabine (CPX-351/Vyxeos), the standard of care is changing rapidly in AML for subgroups. This review will focus on currently approved agents and promising novel agents in development and will highlight controversial areas in targeted treatment.

Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Author(s): 
Slade M, DiPersio J, Westervelt P, Vij R, Schroeder M, Romee R
Primary Author: 
Slade M
Journal Title: 
Biology of Blood and Marrow Transplantation
Original Publication Date: 
Nov 2017

Many hematologic malignancies are diseases of aging, and the use of hematopoietic cell transplant (HCT) is growing rapidly among older adults. Modern post-transplant

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen

Author(s): 
Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS
Primary Author: 
Ali AM
Journal Title: 
Cancer Med
Original Publication Date: 
Oct 2017

Bone Marrow Diseases: 

Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes

Author(s): 
DeZern AE, Binder G, Ni Q, McGuire M, Smith BD
Primary Author: 
DeZern AE
Journal Title: 
Leuk Res
Original Publication Date: 
Oct 2017

Dose reductions or interruptions may be required to manage treatment-associated adverse events among patients with

Bone Marrow Diseases: 

Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway

Author(s): 
Balaian E, Wobus M, Weidner H, Baschant U, Stiehler M, Ehninger G, Bornhäuser M, Hofbauer LC, Rauner M, Platzbecker U
Primary Author: 
Balaian E
Journal Title: 
Haematologica
Original Publication Date: 
Oct 2017

The effects of

Bone Marrow Diseases: 

Cancer specialist shares a diagnosis close to home

“I want you to talk to me like I’m one of your patients, not like I’m your mother.”

My mom’s familiar voice came over the car’s speakers via the Bluetooth connection to my phone as I drove home. She had left a voicemail an hour earlier asking me to call her back, which was never a good sign. My mother, still working as an administrator in Rhode Island at age 74, was not the type to mince words, nor ask for a return call to discuss trivialities. I asked her what was going on.

Orlando

Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.

Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.
Event Date: 
Sat, 11/04/2017 -
8:00am to 3:30pm
Conference Event Type: